Search Results

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study.

B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto™ Intravascular Imaging System.

InfraReDx, Inc. presented a poster at the American College of Cardiology (ACC) 67th Annual Scientific Session supporting the value of combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging technology to identify lipid core plaque (LCP), an underlying cause of serious cardiac events.

PROSPECT ABSORB, a randomized substudy, showed treatment of high risk plaques with BVS is safe and associated with favorable long-term clinical outcomes compared to GDMT alone BEDFORD, Mass.--( BUSINESS WIRE )-- Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect,

A new cardiovascular imaging tool could prevent the possibility of people experiencing a second or third heart attack.

Nipro Vascular Company Brings the First Dual-Modality Intravascular Imaging System and Catheter to the World’s Largest Imaging Market.

The highly anticipated study results will be presented at a late-breaking clinical trial session at TCT on Monday, September 24